NO20015892D0 - Inhibitorer av metallproteinaser - Google Patents

Inhibitorer av metallproteinaser

Info

Publication number
NO20015892D0
NO20015892D0 NO20015892A NO20015892A NO20015892D0 NO 20015892 D0 NO20015892 D0 NO 20015892D0 NO 20015892 A NO20015892 A NO 20015892A NO 20015892 A NO20015892 A NO 20015892A NO 20015892 D0 NO20015892 D0 NO 20015892D0
Authority
NO
Norway
Prior art keywords
inhibitors
metal proteinases
proteinases
metal
arylpiperazines
Prior art date
Application number
NO20015892A
Other languages
English (en)
Other versions
NO20015892L (no
Inventor
Howard Tucker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20015892D0 publication Critical patent/NO20015892D0/no
Publication of NO20015892L publication Critical patent/NO20015892L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
NO20015892A 1999-06-04 2001-12-03 Inhibitorer av metallproteinaser NO20015892L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99401350 1999-06-04
PCT/GB2000/002085 WO2000075108A1 (en) 1999-06-04 2000-05-31 Inhibitors of metalloproteinases

Publications (2)

Publication Number Publication Date
NO20015892D0 true NO20015892D0 (no) 2001-12-03
NO20015892L NO20015892L (no) 2001-12-19

Family

ID=8241999

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015892A NO20015892L (no) 1999-06-04 2001-12-03 Inhibitorer av metallproteinaser

Country Status (17)

Country Link
US (1) US6916817B1 (no)
EP (1) EP1187811B1 (no)
JP (1) JP2003501414A (no)
KR (1) KR20020005769A (no)
CN (1) CN1159295C (no)
AT (1) ATE356114T1 (no)
AU (1) AU773967B2 (no)
BR (1) BR0011339A (no)
CA (1) CA2374460A1 (no)
DE (1) DE60033809T2 (no)
ES (1) ES2281346T3 (no)
IL (1) IL146543A0 (no)
MX (1) MXPA01012322A (no)
NO (1) NO20015892L (no)
NZ (1) NZ515829A (no)
WO (1) WO2000075108A1 (no)
ZA (1) ZA200109675B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
SE0301922D0 (sv) 2003-06-27 2003-06-27 Astrazeneca Ab Novel compounds
GB0427403D0 (en) * 2004-12-15 2005-01-19 Astrazeneca Ab Novel compounds I
KR20080064880A (ko) * 2005-10-26 2008-07-09 라보라뚜와르 세로노 에스. 에이. 술폰아미드 유도체 및 금속단백분해효소를 조정하기 위한그것의 용도
KR100673015B1 (ko) 2005-11-14 2007-01-24 삼성전자주식회사 캐패시터를 갖는 반도체 소자 및 그 형성 방법
GB0617367D0 (en) * 2006-09-02 2006-10-11 Astrazeneca Ab Novel process
WO2008147763A1 (en) * 2007-05-23 2008-12-04 Array Biopharma Inc. Mmp inhibitors and methods of use thereof
EA201792443A1 (ru) 2015-05-06 2018-10-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния МОДУЛЯТОРЫ K-Ras
MX2019012532A (es) 2017-04-20 2019-12-02 Univ California Moduladores de k-ras.
WO2019204449A1 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfone moiety
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas
CN111117990B (zh) * 2020-02-26 2023-03-28 中国医科大学 一种抑制mmp9活性的多肽及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817822A (en) 1994-06-24 1998-10-06 Novartis Corporation Certain alpha-azacycloalkyl substituted arylsulfonamido acetohydroxamic acids
HUP0000941A3 (en) * 1997-01-23 2002-06-28 Hoffmann La Roche Sulfamide derivatives, process for producing them, pharmaceutical compositions containing them and their use
WO1999002510A1 (en) * 1997-07-10 1999-01-21 Pharmacia & Upjohn S.P.A. Matrix metalloproteinase inhibitors
ZA988967B (en) * 1997-10-03 2000-04-03 Du Pont Pharm Co Lactam metalloprotease inhibitors.
ATE346041T1 (de) * 1998-01-30 2006-12-15 Darwin Discovery Ltd N-hydroxyformamid-derivate
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds

Also Published As

Publication number Publication date
ATE356114T1 (de) 2007-03-15
DE60033809T2 (de) 2007-12-06
CN1390200A (zh) 2003-01-08
AU773967B2 (en) 2004-06-10
US6916817B1 (en) 2005-07-12
NZ515829A (en) 2003-10-31
JP2003501414A (ja) 2003-01-14
ZA200109675B (en) 2003-02-24
ES2281346T3 (es) 2007-10-01
AU5090900A (en) 2000-12-28
MXPA01012322A (es) 2002-07-22
DE60033809D1 (de) 2007-04-19
EP1187811B1 (en) 2007-03-07
CA2374460A1 (en) 2000-12-14
WO2000075108A1 (en) 2000-12-14
NO20015892L (no) 2001-12-19
KR20020005769A (ko) 2002-01-17
CN1159295C (zh) 2004-07-28
EP1187811A1 (en) 2002-03-20
IL146543A0 (en) 2002-07-25
BR0011339A (pt) 2002-03-19

Similar Documents

Publication Publication Date Title
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
ATE227264T1 (de) Metalloproteinase-inhibitoren
ATE465146T1 (de) 1h-indolderivate als hochselektive cyclooxygenase-2-inhibitoren
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
UY27972A1 (es) Derivados de hidantoína
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
NO20025811L (no) Forbindelser som er effektive som beta-2-adrenoreseptor- agonister så vel som PDE4-inhibitorer
NO20015892D0 (no) Inhibitorer av metallproteinaser
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BG107003A (en) Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
DE50005444D1 (de) Selektive inhibitoren des urokinase-plasminogen aktivators
NO20023951L (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
DE60202669D1 (de) 6-phenylbenzonaphthyidine
ATE348800T1 (de) 4'-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
ATE269313T1 (de) Tryptase-inhibitoren
DE60228134D1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
DK1244614T3 (da) Tryptase-inhibitorer
NO20024679D0 (no) Krystallinsk farmasöytikum
ATE348803T1 (de) Tryptase-inhibitoren
DE60014915D1 (de) Hypoxanthin- und thiohypxanthin-verbindungen
DK1358182T3 (da) Diazocin-derivater og anvendelsen deraf som tryptase-inhibitorer
ATE364037T1 (de) Tryptasehemmer
UA33865A (uk) Дикалієва сіль n-сукцин - dl-триптофану, що має антиангінальну та антигіпоксантну дію

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application